💨 Abstract

Nektar Therapeutics reported a Q2 loss of $41.6 million, or $2.95 per share, surpassing Wall Street expectations of a $3.13 per share loss. The company's revenue was $11.2 million, also exceeding forecasts of $10.8 million.

Courtesy: WTOP Staff